BioCentury | Aug 10, 2018
Targets & Mechanisms

Getting to function

...protein synthesis, and thereby increasing muscle mass (see Figure: “Tapping Mitochondria”). Figure: Tapping mitochondria A University of Toulouse...
...stair climbing and Activity Measure for Post Acute Care (AM-PAC) Physical Movement Score. Now, a University of Toulouse...
...synthase. “If you normalize metabolism, you normalize pathologies such as sarcopenia or diabetes.” Cedric Dray, University of Toulouse...
BioCentury | Aug 1, 2018
Distillery Therapeutics

Musculoskeletal

...published online July 30, 2018 doi:10.1038/s41591-018-0131-6 CONTACT: Cedric Dray, University of Toulouse, Toulouse, France email: cedric.dray@inserm.fr Jaime De Leon University of Toulouse Apelin...
BioCentury | Jul 30, 2018
Preclinical News

Apelin is a potential sarcopenia therapeutic

...serve as a biomarker of the age-related disease characterized by skeletal muscle loss. Researchers from University of Toulouse...
...and proliferation and myogenic differentiation and repair following cardiotoxin muscle injury in aged mice. Jaime De Leon University of Toulouse Apelin...
BioCentury | Jan 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

...mouse studies suggest a lipopeptide biosynthesized by E. coli clbA could help treat gastrointestinal pain. University of Toulouse...
BioCentury | Dec 19, 2017
Distillery Therapeutics

Neurology

...published online Nov. 3, 2017 doi:10.1038/s41467-017-01403-9 CONTACT: Nicolas Cenac, University of Toulouse, Toulouse, France email: nicolas.cenac@inserm.fr Karen Tkach Tuzman University of Toulouse E...
BioCentury | Apr 7, 2017
Strategy

Pushing for progress in Prader-Willi

...hormone deficiency Marketed Eutropin LG Life Sciences Ltd. (KSE:068870) Growth hormone deficiency Phase III Oxytocin University of Toulouse...
BioCentury | Mar 8, 2017
Distillery Therapeutics

Other

...published online Feb. 21, 2017 doi:10.1073/pnas.1612421114 CONTACT: Jérôme Nigou, University of Toulouse, Toulouse, France email: jerome.nigou@ipbs.fr Hongjiang Li University of Toulouse Mycobacterium...
BioCentury | Jan 28, 2016
Distillery Therapeutics

Therapeutics: Chemokine CC motif ligand 7 (CCL7; MCP3; SCYA6); CC chemokine receptor 3 (CCR3; CD193)

...Laurent, V. et al. Nat. Commun.; published online Jan. 12, 2016 doi:10.1038/ncomms10230 CONTACT: Catherine Muller, University of Toulouse...
BioCentury | Jul 22, 2010
Distillery Therapeutics

Indication: Autoimmune disease

...al. Proc. Natl. Acad. Sci. USA; published online July 6, 2010; doi:10.1073/pnas.0910759107 Contact: Christophe Cazaux, University of Toulouse...
BioCentury | Jul 22, 2010
Distillery Therapeutics

Indication: Cancer

...al. Proc. Natl. Acad. Sci. USA; published online July 6, 2010; doi:10.1073/pnas.0910759107 Contact: Christophe Cazaux, University of Toulouse...
Items per page:
1 - 10 of 10
BioCentury | Aug 10, 2018
Targets & Mechanisms

Getting to function

...protein synthesis, and thereby increasing muscle mass (see Figure: “Tapping Mitochondria”). Figure: Tapping mitochondria A University of Toulouse...
...stair climbing and Activity Measure for Post Acute Care (AM-PAC) Physical Movement Score. Now, a University of Toulouse...
...synthase. “If you normalize metabolism, you normalize pathologies such as sarcopenia or diabetes.” Cedric Dray, University of Toulouse...
BioCentury | Aug 1, 2018
Distillery Therapeutics

Musculoskeletal

...published online July 30, 2018 doi:10.1038/s41591-018-0131-6 CONTACT: Cedric Dray, University of Toulouse, Toulouse, France email: cedric.dray@inserm.fr Jaime De Leon University of Toulouse Apelin...
BioCentury | Jul 30, 2018
Preclinical News

Apelin is a potential sarcopenia therapeutic

...serve as a biomarker of the age-related disease characterized by skeletal muscle loss. Researchers from University of Toulouse...
...and proliferation and myogenic differentiation and repair following cardiotoxin muscle injury in aged mice. Jaime De Leon University of Toulouse Apelin...
BioCentury | Jan 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

...mouse studies suggest a lipopeptide biosynthesized by E. coli clbA could help treat gastrointestinal pain. University of Toulouse...
BioCentury | Dec 19, 2017
Distillery Therapeutics

Neurology

...published online Nov. 3, 2017 doi:10.1038/s41467-017-01403-9 CONTACT: Nicolas Cenac, University of Toulouse, Toulouse, France email: nicolas.cenac@inserm.fr Karen Tkach Tuzman University of Toulouse E...
BioCentury | Apr 7, 2017
Strategy

Pushing for progress in Prader-Willi

...hormone deficiency Marketed Eutropin LG Life Sciences Ltd. (KSE:068870) Growth hormone deficiency Phase III Oxytocin University of Toulouse...
BioCentury | Mar 8, 2017
Distillery Therapeutics

Other

...published online Feb. 21, 2017 doi:10.1073/pnas.1612421114 CONTACT: Jérôme Nigou, University of Toulouse, Toulouse, France email: jerome.nigou@ipbs.fr Hongjiang Li University of Toulouse Mycobacterium...
BioCentury | Jan 28, 2016
Distillery Therapeutics

Therapeutics: Chemokine CC motif ligand 7 (CCL7; MCP3; SCYA6); CC chemokine receptor 3 (CCR3; CD193)

...Laurent, V. et al. Nat. Commun.; published online Jan. 12, 2016 doi:10.1038/ncomms10230 CONTACT: Catherine Muller, University of Toulouse...
BioCentury | Jul 22, 2010
Distillery Therapeutics

Indication: Autoimmune disease

...al. Proc. Natl. Acad. Sci. USA; published online July 6, 2010; doi:10.1073/pnas.0910759107 Contact: Christophe Cazaux, University of Toulouse...
BioCentury | Jul 22, 2010
Distillery Therapeutics

Indication: Cancer

...al. Proc. Natl. Acad. Sci. USA; published online July 6, 2010; doi:10.1073/pnas.0910759107 Contact: Christophe Cazaux, University of Toulouse...
Items per page:
1 - 10 of 10